- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01691248
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) (DEFLECT-1)
DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female 18 years of age or older.
- Females of childbearing potential must be using an adequate and reliable method of contraception (e.g., abstinence, barrier with additional spermicide foam or jelly, intrauterine device, hormonal contraception). Males and females must agree to avoid conception during treatment and for four weeks following the end of study treatment.
- Is undergoing HSCT with planned Fluoroquinolone prophylaxis.
- Informed consent is provided.
Exclusion Criteria:
- Ongoing active CDAD infection (as evidenced by clinical signs of diarrhea along with the presence of either toxin A and/or B [or their respective genes, tcdA and/or tcdB] of C. difficile in the stool) or current treatment for CDAD.
- Undergoing cord blood transplants.
- Has fulminant colitis, toxic megacolon, or ileus.
- A history of inflammatory bowel disease (ulcerative colitis or Crohn's disease).
- Women who are pregnant or are actively breast feeding (all women of childbearing potential must have a negative pregnancy test result prior to dosing study drug).
- Use of any drugs potentially useful in the treatment of CDAD (e.g. oral Vancomycin, Metronidazole, oral Bacitracin, Fusidic Acid, Rifaximin, and Nitazoxanide).
- Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the participant in the study, would make it unlikely for the participant to complete the study, or would confound the results of the study.
- Participation in other clinical research studies utilizing an investigational agent within one month prior to screening and during the study treatment period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fidaxomicin
200 mg Fidaxomicin tablet once daily for no longer than 40 days
|
Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later). Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Other Names:
|
Placebo Comparator: Placebo
Placebo tablet once daily for no longer than 40 days
|
Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later). Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 30 Days Post-treatment Follow-up.
Time Frame: Up to 30 days post-treatment
|
CDAD is defined as follows: Diarrhea: (change in bowel habits with >3 unformed bowel movements in a 24 hour period) and the presence of either toxin A and/or B (or their respective genes, tcdA and/or tcdB) of C. difficile in the stool determined by C. difficile toxin assay.
Wald 95% Confidence Intervals (CI) are presented.
|
Up to 30 days post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 60 Days Post-treatment.
Time Frame: Up to 60 days post-treatment
|
CDAD is defined as follows: Diarrhea: (change in bowel habits with >3 unformed bowel movements in a 24 hour period) and the presence of either toxin A and/or B (or their respective genes, tcdA and/or tcdB) of C. difficile in the stool determined by C. difficile toxin assay.
Wald 95% Confidence Intervals (CI) are presented.
|
Up to 60 days post-treatment
|
Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to Day 70 of Study.
Time Frame: Up to Day 70 of study
|
CDAD is defined as follows: Diarrhea: (change in bowel habits with >3 unformed bowel movements in a 24 hour period) and the presence of either toxin A and/or B (or their respective genes, tcdA and/or tcdB) of C. difficile in the stool determined by C. difficile toxin assay.
Wald 95% Confidence Intervals (CI) are presented.
|
Up to Day 70 of study
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5119-001
- OPT-80-302 (Other Identifier: Optimerpharma Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile-Associated Diarrhea (CDAD)
-
Merck Sharp & Dohme LLCCompletedClostridium Difficile Associated Diarrhea (CDAD)
-
Merck Sharp & Dohme LLCCompletedClostridium Difficile Associated Diarrhea (CDAD)
-
Astellas Pharma Europe B.V.Merck Sharp & Dohme LLCCompletedClostridium Difficile-associated Diarrhea (CDAD)United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
-
University of PittsburghBayer; Shadyside Hospital FoundationTerminatedClostridium Difficile-associated Diarrhea (CDAD)United States
-
Genzyme, a Sanofi CompanyCompletedClostridium Difficile-Associated Diarrhea | Antibiotic-associated Diarrhea | Clostridium Enterocolitis | Clostridium Difficile Diarrhea | Antibiotic-associated ColitisUnited States, Canada, United Kingdom, Puerto Rico
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Optimer Pharmaceuticals LLCCompletedClostridium Difficile-associated Diarrhea
-
Hadassah Medical OrganizationWithdrawnClostridium Difficile-Associated DiarrheaIsrael
-
St. Vincent's East, Birmingham, AlabamaMaster Supplements, IncUnknownDevelopment of Clostridium Difficile Associated DiarrheaUnited States
-
Bio-K Plus International Inc.Sprim Advanced Life SciencesCompletedClostridium Difficile-Associated Diarrhea | Antibiotic-Associated Diarrhea
Clinical Trials on fidaxomicin
-
Astellas Pharma Europe B.V.Merck Sharp & Dohme LLCCompletedClostridium Difficile-associated Diarrhea (CDAD)United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
-
Astellas Pharma Europe Ltd.CompletedInflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
-
Optimer Pharmaceuticals LLCCompletedClostridium Difficile-associated Diarrhea
-
Baylor College of MedicineCubist Pharmaceuticals LLCTerminatedSpinal Cord Injury | Clostridium DifficileUnited States
-
University of Colorado, DenverWithdrawnClostridium Difficile Infection | Solid Organ Transplant
-
Astellas Pharma S.A.S.Completed
-
Astellas Pharma IncCompleted
-
Optimer Pharmaceuticals LLCCompletedDiarrhea | Clostridium Infections
-
University of AlbertaTerminatedClostridium DifficileCanada
-
Benoit GueryRecruitingClostridioides Difficile InfectionSwitzerland